Literature DB >> 28093637

Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting.

Thomas M Atkinson1, Lauren J Rogak2, Narre Heon2, Sean J Ryan2,3, Mary Shaw4, Liora P Stark4, Antonia V Bennett5, Ethan Basch2,5, Yuelin Li4.   

Abstract

PURPOSE: Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient safety, as well as inform decisions related to treatment and continued trial participation. As prior research has demonstrated that conventional concordance metrics (e.g., intraclass correlation) may not capture nuanced aspects of the association between clinician and patient-graded AEs, we aimed to characterize differences in AE grading thresholds between doctors (MDs), registered nurses (RNs), and patients using the Bayesian Graded Item Response Model (GRM).
METHODS: From the medical charts of 393 patients aged 26-91 (M = 62.39; 43% male) receiving chemotherapy, we retrospectively extracted MD, RN and patient AE ratings. Patients reported using previously developed Common Terminology Criteria for Adverse Events (CTCAE) patient-language adaptations called STAR (Symptom Tracking and Reporting). A GRM was fitted to calculate the latent grading thresholds between MDs, RNs and patients.
RESULTS: Clinicians have overall higher average grading thresholds than patients when assessing diarrhea, dyspnea, nausea and vomiting. However, RNs have lower grading thresholds than patients and MDs when assessing constipation. The GRM shows higher variability in patients' AE grading thresholds than those obtained from clinicians.
CONCLUSIONS: The present study provides evidence to support the notion that patients report some AEs that clinicians might not consider noteworthy until they are more severe. The availability of GRM methodology could serve to enhance clinical understanding of the patient symptomatic experience and facilitate discussion where AE grading discrepancies exist. Future work should focus on capturing explicit AE grading decision criteria from MDs, RNs, and patients.

Entities:  

Keywords:  Adverse events; Clinical trials; Clinician–patient agreement; Item response theory; Neoplasms; Patient-reported outcomes

Mesh:

Year:  2017        PMID: 28093637      PMCID: PMC5354957          DOI: 10.1007/s00432-016-2335-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  19 in total

1.  Hip psychometrics.

Authors:  Peter Baldwin; Joseph Bernstein; Howard Wainer
Journal:  Stat Med       Date:  2009-07-30       Impact factor: 2.373

2.  Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.

Authors:  Ethan Basch
Journal:  Value Health       Date:  2012-05       Impact factor: 5.725

3.  The missing voice of patients in drug-safety reporting.

Authors:  Ethan Basch
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

4.  Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities.

Authors:  Ethan Basch; David Artz; Alexia Iasonos; John Speakman; Kevin Shannon; Kai Lin; Charmaine Pun; Henry Yong; Paul Fearn; Allison Barz; Howard I Scher; Mary McCabe; Deborah Schrag
Journal:  J Am Med Inform Assoc       Date:  2007-02-28       Impact factor: 4.497

5.  Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.

Authors:  M Cirillo; M Venturini; L Ciccarelli; F Coati; O Bortolami; G Verlato
Journal:  Ann Oncol       Date:  2009-07-17       Impact factor: 32.976

6.  Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch
Journal:  Qual Life Res       Date:  2013-07-20       Impact factor: 4.147

Review 7.  The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.

Authors:  Thomas M Atkinson; Sean J Ryan; Antonia V Bennett; Angela M Stover; Rebecca M Saracino; Lauren J Rogak; Sarah T Jewell; Konstantina Matsoukas; Yuelin Li; Ethan Basch
Journal:  Support Care Cancer       Date:  2016-06-03       Impact factor: 3.603

8.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Authors:  Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

9.  Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

Authors:  Ethan Basch; William A Wood; Deborah Schrag; Camelia S Sima; Mary Shaw; Lauren J Rogak; Mark G Kris; Marwan Shouery; Antonia Bennett; Thomas Atkinson; M Catherine Pietanza
Journal:  Clin Trials       Date:  2015-11-04       Impact factor: 2.486

Review 10.  New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment.

Authors:  Ethan Basch
Journal:  Annu Rev Med       Date:  2013-11-20       Impact factor: 13.739

View more
  15 in total

1.  Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.

Authors:  Laurie E Steffen McLouth; Thomas W Lycan; Beverly J Levine; Jennifer Gabbard; Jimmy Ruiz; Michael Farris; Stefan C Grant; Nicholas M Pajewski; Kathryn E Weaver; W Jeffrey Petty
Journal:  Clin Lung Cancer       Date:  2019-11-29       Impact factor: 4.785

2.  Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation.

Authors:  Charlene M Fares; Timothy J Williamson; Matthew K Theisen; Amy Cummings; Krikor Bornazyan; James Carroll; Marshall L Spiegel; Annette L Stanton; Edward B Garon
Journal:  JCO Clin Cancer Inform       Date:  2018-12

3.  Symptom Monitoring in Pediatric Oncology Using Patient-Reported Outcomes: Why, How, and Where Next.

Authors:  Allison Barz Leahy; Chris Feudtner; Ethan Basch
Journal:  Patient       Date:  2018-04       Impact factor: 3.883

4.  Sevoflurane versus halothane for induction of anesthesia in pediatric and adult patients.

Authors:  Gouri Kangralkar; Parbati Baburao Jamale
Journal:  Med Gas Res       Date:  2021 Apr-Jun

5.  Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events.

Authors:  Thomas M Atkinson; Bryce B Reeve; Amylou C Dueck; Antonia V Bennett; Tito R Mendoza; Lauren J Rogak; Ethan Basch; Yuelin Li
Journal:  J Patient Rep Outcomes       Date:  2018-12-04

6.  A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events.

Authors:  Shing M Lee; Jieling Miao; Ruby Wu; Joseph M Unger; Ken Cheung; Dawn L Hershman
Journal:  Health Qual Life Outcomes       Date:  2019-08-22       Impact factor: 3.186

Review 7.  Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials.

Authors:  Bonnie Addario; Jan Geissler; Marcia K Horn; Linda U Krebs; Deborah Maskens; Kathy Oliver; Ananda Plate; Erin Schwartz; Nicole Willmarth
Journal:  Health Expect       Date:  2019-11-13       Impact factor: 3.377

8.  Patient-Reported Outcomes in Pediatric Oncology: The Patient Voice as a Gold Standard.

Authors:  Allison Barz Leahy; Angela Steineck
Journal:  JAMA Pediatr       Date:  2020-11-02       Impact factor: 16.193

9.  Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.

Authors:  Teresa M Salgado; Jin Liu; Holly L Reed; Caroline S Quinn; Jillian G Syverson; Jennifer Le-Rademacher; Camden L Lopez; Andreas S Beutler; Charles L Loprinzi; Kiran Vangipuram; Ellen M Lavoie Smith; N Lynn Henry; Karen B Farris; Daniel L Hertz
Journal:  Breast       Date:  2020-03-03       Impact factor: 4.380

10.  Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.

Authors:  Laurie E Steffen McLouth; Fengmin Zhao; Taofeek K Owonikoko; Josephine L Feliciano; Nisha A Mohindra; Suzanne E Dahlberg; James L Wade; Gordan Srkalovic; Bradley W Lash; Joseph W Leach; Ticiana A Leal; Charu Aggarwal; David Cella; Suresh S Ramalingam; Lynne I Wagner
Journal:  Cancer Med       Date:  2020-08-28       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.